These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1769409)

  • 1. Serological profiles as prognostic clues for progressive systemic scleroderma: the Italian experience.
    Parodi A; Puiatti P; Rebora A
    Dermatologica; 1991; 183(1):15-20. PubMed ID: 1769409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis.
    Chorzelski TP; Jablonska S; Beutner EH; Blaszczyk M; Jarzabek-Chorzelska M; Kencka D; Krasny S; Kumar V; Tchórzewska A
    Br J Dermatol; 1985 Oct; 113(4):381-9. PubMed ID: 3877519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological markers in progressive systemic sclerosis: clinical correlations.
    Catoggio LJ; Bernstein RM; Black CM; Hughes GR; Maddison PJ
    Ann Rheum Dis; 1983 Feb; 42(1):23-7. PubMed ID: 6402991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
    Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
    Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Centromere antibodies and antibodies against Scl 70 nucleoprotein in progressive systemic scleroderma. Diagnostic and prognostic significance].
    Meurer M; Scharf A; Luderschmidt C; Braun-Falco O
    Dtsch Med Wochenschr; 1985 Jan; 110(1):8-14. PubMed ID: 3880700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-Scl-70 and anti-centromere autoantibodies. Biological markers of 2 forms of systemic scleroderma].
    Johanet C; Agostini MM; Vayssairat M; Abuaf N
    Presse Med; 1989 Feb; 18(5):207-11. PubMed ID: 2522207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal study of patients with anticentromere antibody.
    Takehara K; Soma Y; Igarashi A; Kikuchi K; Tamaki T; Ishibashi Y
    Dermatologica; 1990; 181(3):202-6. PubMed ID: 2135387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pulmonary manifestation of progressive systemic scleroderma: prognostic value of centromere antibodies and antibodies to Scl-70 nucleoprotein].
    Behr J; König G; Meurer M; Krieg T
    Pneumologie; 1990 Jun; 44(6):822-5. PubMed ID: 2381889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scl 70 antibody--a specific marker of systemic sclerosis.
    Jarzabek-Chorzelska M; Blaszczyk M; Jablonska S; Chorzelski T; Kumar V; Beutner EH
    Br J Dermatol; 1986 Oct; 115(4):393-401. PubMed ID: 3535866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical significance of the anticentromere antibody.
    Miller MH; Littlejohn GO; Davidson A; Jones B; Topliss DJ
    Br J Rheumatol; 1987 Feb; 26(1):17-21. PubMed ID: 3493051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-Scl-70 antibodies in systemic scleroderma].
    Le Thi Huong ; Sauvaget F; Johanet C; De Gennes C; Raguin G; Abuaf N; Blétry O; Guillevin L; Homberg JC; Godeau P
    Ann Dermatol Venereol; 1990; 117(2):103-7. PubMed ID: 2111650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical significance of anti-ENA antibodies and anticentromere antibody (ACA) in patients with sclerodermatous skin changes and Raynaud's phenomenon].
    Uchida K; Kondo H; Kashiwazaki S
    Ryumachi; 1984 Aug; 24(4):241-9. PubMed ID: 6334895
    [No Abstract]   [Full Text] [Related]  

  • 14. Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon.
    Cruz M; Mejia G; Lavalle C; Cortes JJ; Reyes PA
    Clin Rheumatol; 1988 Mar; 7(1):80-6. PubMed ID: 3261675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants.
    McCarty GA; Rice JR; Bembe ML; Barada FA
    Arthritis Rheum; 1983 Jan; 26(1):1-7. PubMed ID: 6337593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies.
    Earnshaw W; Bordwell B; Marino C; Rothfield N
    J Clin Invest; 1986 Feb; 77(2):426-30. PubMed ID: 3511098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical correlation of anticentromere antibodies.
    Zuber M; Gotzen R; Filler I
    Clin Rheumatol; 1994 Sep; 13(3):427-32. PubMed ID: 7835004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
    Kallenberg CG; Pastoor GW; Wouda AA; The TH
    Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinuclear antibodies in progressive systemic sclerosis.
    Riboldi P; Asero R; Origgi L; Crespi S; Meroni PL; Sguotti C; Sabbadini MG
    Clin Exp Rheumatol; 1985; 3(3):205-11. PubMed ID: 3902296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term longitudinal study of anticentromere antibodies.
    Tramposch HD; Smith CD; Senecal JL; Rothfield N
    Arthritis Rheum; 1984 Feb; 27(2):121-4. PubMed ID: 6607733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.